Search results
Results from the WOW.Com Content Network
A myelodysplastic syndrome (MDS) is one of a group of cancers in which blood cells in the bone marrow do not mature, and as a result, do not develop into healthy blood cells. [3] Early on, no symptoms typically are seen. [3] Later, symptoms may include fatigue, shortness of breath, bleeding disorders, anemia, or frequent infections. [3]
Myelodysplastic–myeloproliferative diseases are a category of hematological malignancies which have characteristics of both myelodysplastic and myeloproliferative conditions. [1] When a hematological malignancy is characterised by normal differentiation of cells of myeloid cell line, it is referred to as myeloproliferative.
In medicine, not otherwise specified (NOS) is a subcategory in systems of disease/disorder classification such as ICD-9, ICD-10, or DSM-IV. It is generally used to note the presence of an illness where the symptoms presented were sufficient to make a general diagnosis , but where a specific diagnosis was not made.
Articles relating to the myelodysplastic syndrome, one of a group of cancers in which immature blood cells in the bone marrow do not mature, and as a result, do not develop into healthy blood cells. Early on, no symptoms typically are seen.
This syndrome affects bone marrow cells causing treatment-resistant anemia and myelodysplastic syndromes that may lead to acute myelogenous leukemia. Examination of the bone marrow shows characteristic changes in the megakaryocytes. They are more numerous than usual, small and mononuclear.
Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells. [2] Problems with blood cell formation result in some combination of low red blood cells, low platelets, and low white blood cells. [2]
The French–American–British (FAB) classification systems refers to a series of classifications of hematologic diseases. It is based on the presence of dysmyelopoiesis and the quantification of myeloblasts and erythroblasts. [1] It was first produced in 1976. [2] Types include:
This is a shortened version of the third chapter of the ICD-9: Endocrine, Nutritional and Metabolic Diseases, and Immunity Disorders. It covers ICD codes 240 to 279 . The full chapter can be found on pages 145 to 165 of Volume 1, which contains all (sub)categories of the ICD-9.